Arvinas Inc
ARVN13.480USD
+0.520+4.01%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
954.38MCap. mercado
PérdidaP/E TTM
Más Datos de Arvinas Inc Compañía
Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.
Información de Arvinas Inc
Símbolo de cotizaciónARVN
Nombre de la empresaArvinas Inc
Fecha de salida a bolsaSep 27, 2018
Director ejecutivoDr. John G. Houston, Ph.D.
Número de empleados430
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 27
Dirección5 Science Park
CiudadNEW HAVEN
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal06511-1966
Teléfono12035351456
Sitio Webhttps://www.arvinas.com/
Símbolo de cotizaciónARVN
Fecha de salida a bolsaSep 27, 2018
Director ejecutivoDr. John G. Houston, Ph.D.
Ejecutivos de Arvinas Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. John G. Houston, Ph.D.
Dr. John G. Houston, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
912.27K
-7.52%
Dr. Angela Cacace, Ph.D.
Dr. Angela Cacace, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
74.86K
-3.34%
Dr. Noah Berkowitz, M.D., Ph.D.
Dr. Noah Berkowitz, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
66.81K
+827.20%
Ms. Leslie V. Norwalk, Esq.
Ms. Leslie V. Norwalk, Esq.
Independent Director
Independent Director
26.05K
+159.93%
Mr. Everett V. Cunningham
Mr. Everett V. Cunningham
Independent Director
Independent Director
26.05K
+159.93%
Dr. Sunil Agarwal, M.D.
Dr. Sunil Agarwal, M.D.
Independent Director
Independent Director
24.67K
+185.35%
Mr. Edward (Ted) Kennedy, Jr.
Mr. Edward (Ted) Kennedy, Jr.
Independent Director
Independent Director
--
--
Ms. Linda C. Bain
Ms. Linda C. Bain
Independent Director
Independent Director
--
--
Mr. Andrew Saik
Mr. Andrew Saik
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Dr. Laurie Smaldone Alsup, M.D.
Dr. Laurie Smaldone Alsup, M.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. John G. Houston, Ph.D.
Dr. John G. Houston, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
912.27K
-7.52%
Dr. Angela Cacace, Ph.D.
Dr. Angela Cacace, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
74.86K
-3.34%
Dr. Noah Berkowitz, M.D., Ph.D.
Dr. Noah Berkowitz, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
66.81K
+827.20%
Ms. Leslie V. Norwalk, Esq.
Ms. Leslie V. Norwalk, Esq.
Independent Director
Independent Director
26.05K
+159.93%
Mr. Everett V. Cunningham
Mr. Everett V. Cunningham
Independent Director
Independent Director
26.05K
+159.93%
Dr. Sunil Agarwal, M.D.
Dr. Sunil Agarwal, M.D.
Independent Director
Independent Director
24.67K
+185.35%
Desglose de ingresos
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2023
La empresa aún no ha revelado los datos relevantes.
Por regiónUSD
Nombre
Ganancia
Proporción
United States
0.00
0.00%
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: jue., 5 de feb
Actualizado: jue., 5 de feb
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
11.23%
BlackRock Institutional Trust Company, N.A.
8.05%
Pfizer Inc
5.38%
D. E. Shaw & Co., L.P.
5.30%
Logos Global Management LP
3.89%
Otro
66.13%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
11.23%
BlackRock Institutional Trust Company, N.A.
8.05%
Pfizer Inc
5.38%
D. E. Shaw & Co., L.P.
5.30%
Logos Global Management LP
3.89%
Otro
66.13%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
36.71%
Hedge Fund
26.23%
Investment Advisor/Hedge Fund
21.31%
Venture Capital
6.56%
Corporation
5.38%
Research Firm
4.23%
Individual Investor
2.59%
Pension Fund
0.53%
Bank and Trust
0.31%
Participación institucional
Actualizado: lun., 8 de dic
Actualizado: lun., 8 de dic
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
513
61.93M
168.36%
-2.99M
2025Q3
525
64.92M
150.53%
-4.18M
2025Q2
518
67.55M
122.76%
+4.71M
2025Q1
504
63.19M
117.99%
-22.92M
2024Q4
484
75.18M
115.79%
+228.04K
2024Q3
476
75.20M
114.63%
+1.35M
2024Q2
469
73.21M
109.58%
+2.16M
2024Q1
476
70.86M
103.71%
+13.21K
2023Q4
483
66.87M
80.36%
+15.93M
2023Q3
458
50.77M
99.64%
+2.00M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
8.55M
13.31%
-831.93K
-8.87%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
5.17M
8.05%
-87.00K
-1.65%
Sep 30, 2025
Pfizer Inc
3.46M
5.38%
--
--
Sep 30, 2025
D. E. Shaw & Co., L.P.
3.41M
5.3%
+57.86K
+1.73%
Nov 06, 2025
Logos Global Management LP
2.50M
3.89%
-3.08M
-55.16%
Oct 14, 2025
Millennium Management LLC
2.13M
3.32%
+233.48K
+12.30%
Sep 30, 2025
State Street Investment Management (US)
1.87M
2.92%
+140.76K
+8.13%
Sep 30, 2025
Geode Capital Management, L.L.C.
1.67M
2.6%
+85.09K
+5.37%
Sep 30, 2025
TCG Crossover Management, LLC
1.62M
2.52%
+1.62M
--
Sep 30, 2025
New Leaf Venture Partners LLC
1.59M
2.47%
--
--
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.76%
State Street SPDR S&P Pharmaceuticals ETF
1.65%
Virtus LifeSci Biotech Clinical Trials ETF
0.91%
Invesco NASDAQ Future Gen 200 ETF
0.7%
iShares U.S. Pharmaceuticals ETF
0.28%
Federated Hermes MDT Small Cap Core ETF
0.24%
Zacks Small/Mid Cap ETF
0.22%
iShares Health Innovation Active ETF
0.16%
ProShares Ultra Nasdaq Biotechnology
0.11%
Invesco RAFI US 1500 Small-Mid ETF
0.1%
Ver más
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporción1.76%
State Street SPDR S&P Pharmaceuticals ETF
Proporción1.65%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.91%
Invesco NASDAQ Future Gen 200 ETF
Proporción0.7%
iShares U.S. Pharmaceuticals ETF
Proporción0.28%
Federated Hermes MDT Small Cap Core ETF
Proporción0.24%
Zacks Small/Mid Cap ETF
Proporción0.22%
iShares Health Innovation Active ETF
Proporción0.16%
ProShares Ultra Nasdaq Biotechnology
Proporción0.11%
Invesco RAFI US 1500 Small-Mid ETF
Proporción0.1%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
